Payment overview · 2025
General Payments
$1,319.46
67 reported records · 18 companies
Healthcare provider profile · identity verified
Tara Bozek
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · UNIONTOWN, PA · NPI 1144751892
Verified facts
What the public records show
CMS Open Payments records show Tara Bozek received $1,319.46 in general payments during 2025 across 67 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $325.51 | 24.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $224.53 | 17.0% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.05 | 16.1% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $157.96 | 12.0% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $78.69 | 6.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.80 | 5.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.34 | 2.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.66 | 2.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.14 | 2.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.79 | 1.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.75 | 1.6% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $18.50 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.89 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.52 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.76 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.50 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.01 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.06 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,319.46 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $281.28 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $197.22 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $152.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $142.55 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $94.86 | 8 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $78.69 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $78.69 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.94 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $62.75 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.15 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.15 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.58 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.58 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.58 | 3 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.11 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 190 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
190 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 105 |
| Lisinopril | Lisinopril | 326 | 88 |
| Metformin Hcl | Metformin Hcl | 266 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 249 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 229 | 65 |
| Potassium Chloride | Potassium Chloride | 207 | 46 |
| Losartan Potassium | Losartan Potassium | 196 | 54 |
| Ozempic | Semaglutide | 190 | 35 |
| Sertraline Hcl | Sertraline Hcl | 186 | 48 |
| Omeprazole | Omeprazole | 184 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 45 |
| Gabapentin | Gabapentin | 165 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 45 |
| Furosemide | Furosemide | 132 | 40 |
| Eliquis | Apixaban | 122 | 22 |
| Simvastatin | Simvastatin | 112 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 33 |
| Montelukast Sodium | Montelukast Sodium | 102 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 17 |
| Prednisone | Prednisone | 89 | 69 |
| Famotidine | Famotidine | 87 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 24 |
| Alprazolam | Alprazolam | 85 | 23 |
| Carvedilol | Carvedilol | 85 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Buspirone Hcl | Buspirone Hcl | 80 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 59 |
| Synthroid | Levothyroxine Sodium | 68 | 16 |
| Trazodone Hcl | Trazodone Hcl | 66 | 23 |
| Mounjaro | Tirzepatide | 65 | 15 |
| Irbesartan | Irbesartan | 59 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 30 |
| Ezetimibe | Ezetimibe | 55 | 18 |
| Jardiance | Empagliflozin | 55 | 15 |
| Atenolol | Atenolol | 50 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 24 |
| Glimepiride | Glimepiride | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 17 |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Alendronate Sodium | Alendronate Sodium | 43 | 16 |
| Spironolactone | Spironolactone | 41 | 14 |
| Valsartan | Valsartan | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | 14 |
| Ibuprofen | Ibuprofen | 34 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 13 |
| Azithromycin | Azithromycin | 33 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Tradjenta | Linagliptin | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,319.46 · 67 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROCLAIM, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VYNDAMAX, Veozah, WATCHMAN Access System, Wegovy, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error